Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy

BACKGROUND: Immune checkpoint inhibitors (ICI) are now standard-of-care treatment for patients with metastatic gastric cancer (GC). To guide patient selection for ICI therapy, programmed death ligand-1 (PD-L1) biomarker expression is routinely assessed via immunohistochemistry (IHC). However, with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeong, Joe, Lum, Huey Yew Jeffrey, Teo, Chong Boon, Tan, Benjamin Kye Jyn, Chan, Yiong Huak, Tay, Ryan Yong Kiat, Choo, Joan Rou-En, Jeyasekharan, Anand D., Miow, Qing Hao, Loo, Lit-Hsin, Yong, Wei Peng, Sundar, Raghav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226082/
https://www.ncbi.nlm.nih.gov/pubmed/35661944
http://dx.doi.org/10.1007/s10120-022-01301-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226082/
https://www.ncbi.nlm.nih.gov/pubmed/35661944
http://dx.doi.org/10.1007/s10120-022-01301-0

Ejemplares similares